This contract involves establishing active ingredient-based discount agreements in accordance with § 130a Abs. 8 SGB V for specific pharmaceuticals. The agreements will be in effect for a maximum period of 24 months, starting no earlier than April 1, 2026, and ending uniformly on March 31, 2028. Sup
The contract involves the delivery of a range of pharmaceuticals. The total value of the contract is approximately €538,742.40. This opportunity is aimed at suppliers in the health sector, specifically for the provision of diverse medicinal products. The contract is awarded by the Federal Office for
This procurement process is not subject to public procurement law. It is an Open-House procedure aimed at ensuring transparency and broad information dissemination to interested pharmaceutical companies. This announcement is published in the Supplement to the Official Journal of the European Union.
